Literature DB >> 22433671

Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence.

Francis C H Ho1, Ivan W K Tham, Arul Earnest, Khai Mun Lee, Jiade J Lu.   

Abstract

BACKGROUND: The characteristics of cervical lymphatic metastasis in nasopharyngeal carcinoma (NPC) are not completely understood. As such, radiotherapy to the entire lymphatic of the neck bilaterally has been empirically practiced even in early stage disease, although not supported by clinical evidence. We studied the pattern and probability of nodal metastasis through a meta-analysis of published evidences, with an aim to establish an evidence-based guideline for selecting and delineation of clinical target volume of neck lymphatics for conformation radiation for NPC.
METHODS: A literature search yielded an initial 411 original articles, and 13 studies with 2920 NPC cases staged via MRI were included in this analysis. The occurrence of nodal metastasis was calculated and analyzed according to the respective regional nodal levels.
RESULTS: 85% of NPC cases presented with lymphadenopathy. The most commonly involved regions include retropharyngeal (69%) and level II lymph nodes (70%). The overall probability of levels III, IV, and V nodal involvement are 45%, 11%, and 27%, respectively. Low-risk node groups included the supraclavicular, levels IA/IB and VI nodes, and parotid nodes with involvement rates at 3%, 0%, 3%, 0%, and 1%, respectively. Nodal metastases followed an orderly pattern and the probability of "skip" metastasis between levels varied between 0.5-7.9%.
CONCLUSIONS: Lymph node metastasis in NPC follows a predictable and orderly pattern. The rarity of metastasis in certain nodal groups and "skip" metastasis suggest that reduced treatment volume is feasible in conformal radiotherapy for NPC.

Entities:  

Mesh:

Year:  2012        PMID: 22433671      PMCID: PMC3353248          DOI: 10.1186/1471-2407-12-98

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  32 in total

1.  Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma.

Authors:  Wai Tong Ng; Michael C H Lee; Wai Man Hung; Cheuk Wai Choi; Kin Chung Lee; Oscar S H Chan; Anne W M Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-06       Impact factor: 7.038

2.  Staging of nasopharyngeal carcinoma investigated by magnetic resonance imaging.

Authors:  Jin-Cheng Lu; Bao-Qing Wei; Wen-Zhan Chen; Pu-Dong Qian; Yi-Qin Zhang; Qing Wei; Wen-Wu Cha; Feng Li; Ming Ni
Journal:  Radiother Oncol       Date:  2006-04-19       Impact factor: 6.280

3.  The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging.

Authors:  Linglong Tang; Yanping Mao; Lizhi Liu; Shaobo Liang; Yong Chen; Ying Sun; Xinbiao Liao; Aihua Lin; Mengzhong Liu; Li Li; Jun Ma
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

4.  Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

Authors:  Nancy Lee; Jonathan Harris; Adam S Garden; William Straube; Bonnie Glisson; Ping Xia; Walter Bosch; William H Morrison; Jeanne Quivey; Wade Thorstad; Christopher Jones; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-06-29       Impact factor: 44.544

5.  Magnetic resonance imaging of retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: patterns of spread.

Authors:  Li-Zhi Liu; Guo-Yi Zhang; Chuang-Miao Xie; Xue-Wen Liu; Chun-Yan Cui; Li Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

6.  N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: pattern of nodal involvement by radiological levels.

Authors:  Wai T Ng; Anne W M Lee; Wai K Kan; John Chan; Ellie S Y Pang; Tsz K Yau; Kam Y Lau
Journal:  Radiother Oncol       Date:  2006-12-12       Impact factor: 6.280

7.  How does magnetic resonance imaging influence staging according to AJCC staging system for nasopharyngeal carcinoma compared with computed tomography?

Authors:  Xin-Biao Liao; Yan-Ping Mao; Li-Zhi Liu; Ling-Long Tang; Ying Sun; Yan Wang; Ai-Hua Lin; Chun-Yan Cui; Li Li; Jun Ma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

8.  Patterns of level II node metastasis in nasopharyngeal carcinoma.

Authors:  XiaoShen Wang; LongGen Li; ChaoSu Hu; ZhengRong Zhou; HongMei Ying; JianHui Ding; Yan Feng
Journal:  Radiother Oncol       Date:  2008-09-01       Impact factor: 6.280

9.  18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis.

Authors:  Panayiotis A Kyzas; Evangelos Evangelou; Despina Denaxa-Kyza; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2008-05-13       Impact factor: 13.506

10.  Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors.

Authors:  Anne W M Lee; W T Ng; W M Hung; C W Choi; Raymond Tung; Y H Ling; Peter T C Cheng; T K Yau; Amy T Y Chang; Samuel K C Leung; Michael C H Lee; Soren M Bentzen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-23       Impact factor: 7.038

View more
  89 in total

1.  Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes.

Authors:  F Xiao; S Dou; Y Li; W Qian; F Liang; L Kong; X Wang; K Wu; C Hu; G Zhu
Journal:  Clin Transl Oncol       Date:  2018-12-04       Impact factor: 3.405

2.  Reduced expression of polymeric immunoglobulin receptor (pIgR) in nasopharyngeal carcinoma and its correlation with prognosis.

Authors:  Xuanchang Qi; Xuechang Li; Xiuxia Sun
Journal:  Tumour Biol       Date:  2016-02-24

3.  Diffusion-weighted imaging to differentiate metastatic from non-metastatic retropharyngeal lymph nodes in nasopharyngeal carcinoma.

Authors:  H Li; X-W Liu; Z-J Geng; D-L Wang; C-M Xie
Journal:  Dentomaxillofac Radiol       Date:  2014-11-28       Impact factor: 2.419

Review 4.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

5.  Sparing level Ib lymph nodes by intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma.

Authors:  Jing Chen; Dan Ou; Xiayun He; Chaosu Hu
Journal:  Int J Clin Oncol       Date:  2013-12-12       Impact factor: 3.402

6.  Submandibular mass as a rare presentation of advanced nasopharyngeal carcinoma.

Authors:  I Mohamad; M Y Kosha
Journal:  Malays Fam Physician       Date:  2013-12-31

7.  Contribution of Nitric oxide synthase 3 genetic variants to nasopharyngeal carcinoma risk and progression in a Tunisian population.

Authors:  Sahar Aouf; Ala Laribi; Sallouha Gabbouj; Elham Hassen; Noureddine Bouaouinaa; Abdelfattah Zakhama; Hedi Harizi
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-13       Impact factor: 2.503

Review 8.  Frontiers of cancer imaging and guided therapy using ultrasound, light, and microwaves.

Authors:  Russell S Witte; Chandra Karunakaran; Andres N Zuniga; Hannah Schmitz; Hina Arif
Journal:  Clin Exp Metastasis       Date:  2018-08-04       Impact factor: 5.150

9.  Prognostic value and differences of the sixth and seventh editions of the UICC/AJCC staging systems in nasopharyngeal carcinoma.

Authors:  Rui Sun; Hui-Zhi Qiu; Hai-Qiang Mai; Qing Zhang; Ming-Huang Hong; Yan-Xian Li; Jing Yang; Jian Sun; Hao-Yuan Mo
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-16       Impact factor: 4.553

10.  Thyroid adenoma and nasopharyngeal carcinoma with metastasis to cervical lymph nodes is misdiagnosed and treated for thyroid carcinoma: A case report.

Authors:  Miao Zhang; Heng Wang; Xuefeng Pan; Wenbin Wu; Hui Zhang
Journal:  Oncol Lett       Date:  2016-05-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.